In short
This article summarizes several clinical trials investigating the use of MPS-215, a component of the cancer vaccine TEDOPI (OSE2101), for treating various advanced cancers including non-small cell lung cancer, ovarian cancer, and pancreatic cancer. TEDOPI contains multiple peptides including MPS-215 and is being studied alone and in combination with other therapies as a potential immunotherapy treatment option for patients with advanced cancers.
What is MPS-215?
MPS-215 is one of the key components of TEDOPI, an innovative cancer vaccine being developed by OSE Immunotherapeutics. TEDOPI, also known as OSE2101, EP2101, or IDM2101, is a combination of 10 synthetically manufactured peptides, including MPS-215. This vaccine is designed to stimulate the immune system to fight against certain types of cancer.
How Does MPS-215 Work?
As part of the TEDOPI vaccine, MPS-215 works by activating the body's immune system to recognize and attack cancer cells. The vaccine is specifically designed for patients with a particular genetic profile called HLA-A2 positive. This means that the vaccine is tailored to work with the patient's own immune system, potentially making it more effective than traditional treatments for some patients.
What Conditions Does MPS-215 Treat?
MPS-215, as part of the TEDOPI vaccine, is being studied for the treatment of several types of cancer, including:
- Non-Small Cell Lung Cancer (NSCLC): This is the most common type of lung cancer, accounting for about 80-85% of all lung cancers.
- Ovarian Cancer: Specifically, it's being studied for platinum-sensitive recurrent ovarian cancer.
- Pancreatic Cancer: The vaccine is being tested in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
Clinical Trials Involving MPS-215
Several clinical trials are currently underway to evaluate the effectiveness of TEDOPI, which includes MPS-215:
- ARTEMIA Study: This is a phase 3 trial comparing TEDOPI to docetaxel in patients with advanced non-small cell lung cancer who have developed resistance to immune checkpoint inhibitors.
- TEDOVA Study: This phase 2 trial is evaluating TEDOPI alone or in combination with pembrolizumab as a maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer.
- TEDOPAM Study: This phase 2 study is looking at TEDOPI plus FOLFIRI chemotherapy as a maintenance therapy for patients with advanced pancreatic cancer.
How is MPS-215 Administered?
MPS-215, as part of the TEDOPI vaccine, is administered as a subcutaneous injection (an injection under the skin). The exact dosing schedule may vary depending on the specific clinical trial and the condition being treated. In some studies, patients receive up to 13 injections over a period of about two years.
Potential Side Effects
As with any medical treatment, there may be potential side effects associated with TEDOPI, including MPS-215. While specific side effects for MPS-215 alone are not detailed in the provided information, cancer vaccines in general may cause:
- Injection site reactions (redness, swelling, or pain at the injection site)
- Flu-like symptoms (fever, chills, fatigue)
- Muscle or joint pain
- Nausea
- Headache
It's important to note that the safety profile of TEDOPI is still being evaluated in clinical trials. Patients should discuss potential risks and benefits with their healthcare provider.
Conclusion
MPS-215, as a component of the TEDOPI cancer vaccine, represents a promising approach in cancer immunotherapy. By harnessing the power of the body's own immune system, this treatment aims to provide a more targeted and potentially more effective option for certain cancer patients. While still in clinical trials, the results of these studies will help determine the future role of MPS-215 and TEDOPI in cancer treatment.